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Introduction
Elevated concentrations of homocysteine (Hcy), the basis of 
hyperhomocysteinaemia (HHcy), are involved in a myriad of 
diseases, including cardiovascular disease (CVD),1,2 and various 
other conditions, such as impaired bone health,3 inflammatory 
bowel disease4 and cancer.5 The underlying causes of HHcy arise 
from the interplay of genetic, biological and environmental factors, 
which can roughly be divided into two groups: those that are 
unchangeable, such as genetics, gender and advancing age; and 
modifiable factors, including smoking, diet and physical activity. 
In addition, acquired conditions, such as diseases (renal failure, 
rheumatoid arthritis, malignancies, psoriasis and infection with the 
human immunodeficiency virus) and certain drugs (methotrexate, 
nitrous oxide, theophylline and thiazides) can also lead to elevated 
Hcy concentrations.
Since Hcy can be lowered by diet, the nutritionist and dietitian can 
play an important role in the prevention and therapeutic treatment of 
individuals at increased risk of diseases that are contingent on Hcy. 
The metabolism of Hcy and dietary determinants explored in this 
review equip these professionals with the knowledge to treat HHcy 
in ways that are simple, inexpensive and safe.
An overview of the biochemistry and metabolism of 
homocysteine
Hcy is a sulphur‑containing amino acid, i.e. a thiol (−SH), with the 
chemical formula: HSCH2CH2CH(NH2)CO2H.
6 Hcy is not present in 
food, but is formed by the body as it metabolises methionine, an 
essential amino acid.7
The structures of methionine and Hcy are identical, except for 
a conversion that results in removing a one‑carbon methyl group 
(−CH3) from the former.
8 While methionine is chemically stable, the 
free thiol of Hcy renders it highly reactive in cells and within the 
circulation.7 Seventy per cent to eighty per cent of Hcy is bound to 
the thiol groups of plasma proteins in human plasma.7 Only 1‑4% 
circulates as free Hcy in its reduced form, whereas the remainder 
auto‑oxidises to form homocystine dimers, or combines with 
other thiols, such as cysteine (Cys) and glutathione to form mixed 
disulphides.6,9 It is not yet clear which complexes are formed by the 
reduced Hcy molecules within cells, but it seems probable, with the 
reactivity of the thiol group of Hcy, that similar complexes will form.7
The metabolism of B vitamins, methyl groups and Hcy is inextricably 
linked (Figure 1). The clearance of Hcy from the human circulation 
depends on folate, vitamin B2, vitamin B6 and vitamin B12.
In cells there are approximately 28 enzymes that can be identified as 
methyltransferases. Methyltransferases are involved in the donation 
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(or transfer) of a methyl group from the activated form of methionine, 
namely, S‑adenosylmethionine (SAM), to the synthesis of thymine, 
choline, creatine, epinephrine, the protein 3‑methylhistidine or for 
deoxyribonucleic acid methylation.7 Methionine adenosyl‑transferase 
converts methionine to SAM by a reaction that includes the addition 
of a methyl group and the purine base, adenine (from adenosine 
triphosphate or diphosphate). When SAM donates a methyl group, it 
is converted to S‑adenosylhomocysteine (SAH). All SAM‑dependent 
methyltransferase reactions result in the production of SAH, which 
can be catabolised immediately in vivo by SAH hydrolase to produce 
the nucleotide adenosine and Hcy.7,11 While the accumulation of SAH 
might in itself impair cellular function by inhibiting methyltransferase 
enzymes, thereby preventing the repair of aged or damaged cells,12 
Hcy, with its reactive free thiol group, could also be toxic to cells in 
its own right.7
Hcy can follow three possible pathways within cellular metabolism. 
First, Hcy may be remethylated back to methionine by either 
folate‑dependent or folate‑independent mechanisms.11 During 
folate‑dependent remethylation, methionine synthase (MS) uses 
a methyl group from 5‑methyltetrahydrofolate (5‑MTHF), while 
methylcobalamin (the biologically active form of vitamin B
12) acts 
as the coenzyme. The methyl group for this reaction is produced 
by the enzyme 5,10‑MTHFR. MTHFR, in turn, uses flavin adenine 
dinucleotide (the biologically active form of vitamin B
2) as a co‑
factor.13 In an alternative folate‑independent remethylation route, 
the enzyme betaine-homocysteine methyltransferase (BHMT) 
catalyses the remethylation of Hcy using betaine (trimethylglycine, 
which is a generator of methionine and SAM), a methyl group donor 
derived from choline oxidation, to convert Hcy to methionine and 
dimethylglycine. BHMT catalyses the synthesis of methionine from 
betaine and Hcy, using a zinc ion to activate Hcy.14 Its expression 
is induced in mice on a methionine‑deficient diet.15 SAM seems to 
function as a switch between the methionine cycle and the trans‑
sulphuration pathway. When SAM concentrations become limited, 
SAH and Hcy concentrations increase, and there is an accompanying 
reduction in the methylation cycle.16 High SAM concentrations seem 
to limit Hcy remethylation by inhibiting MTHF and BHMT. Trans‑
sulphuration seems to be enhanced by the stimulatory effect of SAM 
on cystathionine by cystathionine β‑synthase (CBS) activity.16 This 
interplay is necessary for Hcy homeostasis and to prevent diseases 
contingent on HHcy.
Second, Hcy can be catabolised further to Cys by trans‑sulphuration 
using pyridoxal 5’‑phosphate (PLP) (the biologically active form of 
vitamin B
6) as a co‑factor, beginning with the irreversible conversion 
to CBS. The enzyme, cystathionine γ‑lyase (CSE or cystathionase), 
then uses CSE to form Cys, which is required for the synthesis 
of many compounds, including glutathionine, or can be further 
converted to pyruvate, which can be used for energy and sulphate, 
which is excreted through the urine.7 While the trans‑sulphuration 
pathway contributes to the maintenance of normal postprandial Hcy 
concentrations, the remethylation pathway maintains normal fasting 
Hcy concentrations.17
Third, excess Hcy can be exported from the cell into the circulation, 
thereby regulating the intracellular Hcy concentrations.7,16 Earlier 
studies have indicated that the normal reference range for total 
plasma Hcy (i.e. the sum of free and protein‑bound Hcy, Hcy and Hcy‑
Cys mixed disulphide) is 5‑15 μmol/l (to convert Hcy concentration 
to μg/ml, multiply by 0.1352), mild to moderate HHcy between 
16 µmol/l and 100 μmol/l, and severe HHcy > 100 μmol/l.18,19 In 
Figure 1:  Homocysteine and folate metabolism10
5‑MTHF: 5‑methyltetrahydrofolate, 5,10‑MTHF: 5,10‑methylenetetrahydrofolate, BBM: brush border membrane, BHMT: betaine‑homocysteine methyltransferase, BLM: basolateral membrane, CBS: cystathionine 
β‑synthase, CSE: cystathionine γ‑lyase, GCP II: glutamate carboxypeptidase II, Hcy: homocysteine, MS: methionine synthase, MTHFR: methylenetetrahydrofolate reductase, RFC I: reduced folate carrier 1, SAH: 
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2007, Castañon, Lauricella, Kordich and Quintana1 calculated that 
Hcy concentrations of > 12 μmol/l significantly increased the risk 
of developing venous thrombosis. Since the definition of elevated 
circulating Hcy concentrations should ideally be based on a health 
outcome, they proposed the use of 12 μmol/l as a cut‑off value for 
HHcy, with clinical significance relating to CVD. The American Heart 
Association Nutrition Committee has recommended that basal Hcy 
should be 10 µmol/l as a therapeutic goal for subjects at increased 
risk of CVD.19 Cut‑off values for diseases associated with Hcy other 
than CVD should be established in future studies.
It is important to note that standardisation of the methods 
(chromatography, capillary electrophoresis and immunoassays) 
used to quantify Hcy is still needed, since between‑method and 
inter‑laboratory variations in total Hcy quantification are not yet 
satisfactory.20‑22 According to Ubbink,22 fluorescence polarisation 
immunoassay may become the choice method for routine diagnostic 
laboratories.
Dietary determinants of homocysteine concentrations
The previously referred to description of the metabolism of Hcy 
shows that nutrition plays a major role in Hcy concentrations.
B vitamin intake
Insufficient B vitamin intake increases Hcy concentrations, and 
induces an imbalance of SAM and SAH,23 whereas supplementation 
with B vitamins and their synthetic counterparts seems to reduce 
Hcy concentrations.24 Hcy has been proposed to be a highly sensitive 
indicator of folate and vitamin B12 status.
25
Folate status
Folate is a micronutrient found in green leafy vegetables and in 
some animal products, such as egg yolk. It is an important co‑factor 
and methyl donor in converting Hcy to methionine. Reduced folate 
status inhibits the methylation cycle by failing to keep it supplied 
with methyl groups, resulting in reduced Hcy remethylation.26 Folate 
deficiency, due to problems of malabsorption or inadequate dietary 
intake (malnutrition or alcoholism), is considered to be the most 
important nutritional cause of elevated Hcy.27
Although everyone should consume sufficient folate, research 
highlights the necessity of adequate folate intake in drinkers of 
alcohol, as well as individuals who harbour the cytosine to thymine 
substitution at nucleotide position 677 (C677T) in the MTHFR 
gene, i.e. 677 TT genotype.28‑30 Chiuve et al28 reported that the 
adverse effects of moderate, but not excessive, alcohol use on Hcy 
concentrations may be overcome through adequate folate intake. 
MTHFR 677 TT homozygous individuals may require more folate for 
thermolabile MTHFR to function adequately and to ensure normal 
Hcy concentrations, than individuals who harbour the wild type 
alleles.29 The adverse effects of a low intake of the methyl‑related 
nutrients, including folate, with a high intake of alcohol, are additive 
in relation to cancer risk.30
A high intake of natural folate from food reduces plasma Hcy 
concentrations,31 but folic acid (a synthetic chemically stable form of 
folate used in supplements and fortified foods) has been reported to 
be more effective than dietary folate in this regard, probably owing 
to its high bioavailability.32 Fasting Hcy concentrations decreased 
modestly after mandatory folic acid fortification in America in 1998.33 
Supplementation with folic acid alone, and in combination with other 
B vitamins, diminishes Hcy concentration.34 It was concluded in a 
meta‑analysis of 25 randomised controlled trials34 that ≥ 0.8 mg 
folic acid per day is required to achieve the maximal reduction in 
Hcy concentration, and that 0.2 mg and 0.4 mg were associated 
with a 60% and 90%, reduction of the maximal effect, respectively. 
Vitamin B12 (0.4 mg/day) produced a further reduction of 7% [95% 
confidence interval (CI): 4‑9%] in Hcy concentrations, but vitamin B6 
had no significant effect.
Evidence suggests that folic acid supplementation has a beneficial 
effect on the vascular endothelium by reducing Hcy, and through 
other mechanisms, for instance, by reducing oxidative stress.35 In 
addition, acute administration of folic acid can restore impaired 
endothelial function induced by acute HHcy.36 Folic acid was reported 
to have antioxidant properties and direct scavenging effects in vitro,37 
and may directly improve nitric oxide production by enhancing the 
enzymatic activity of nitric oxide synthase.38 Hcy leads to increased 
cell proliferation and cell death through apoptosis and necrosis in 
vitro in smooth muscle cells,39 but adding folic acid to the culture 
medium leads to a significant reduction of Hcy concentrations in 
media. This is probably because of the increased remethylation of 
Hcy to methionine, and the reduced effects of Hcy on proliferation, 
apoptosis and necrosis.39
Mager et al40 reported that long‑term folate‑based vitamin therapy 
was independently associated with lower all‑cause mortality in 
HHcy patients with CVD, and with reduced Hcy concentrations. By 
contrast, Albert et al41 reported that long‑term supplementation with 
folic acid, and vitamins B6 and B12, did not reduce total CVD events in 
high‑risk women, despite lowering Hcy significantly.
Riboflavin status
Riboflavin, or 7,8‑dimethyl‑10‑ribityl‑isoalloxazine (vitamin B2), is 
present in a wide variety of foods. It is an essential precursor for the 
biosynthesis of the biologically active flavin adenine mononucleotide 
(FMN) and flavin adenine dinucleotide (FAD). FMN and FAD participate 
in a range of redoxication reactions, some of which are key to the 
function of aerobic cells.42 FAD is an essential co‑factor for the 
folate‑dependent enzyme, MTHFR, which metabolises folate to the 
form used in Hcy methylation, and for an enzyme that activates the 
vitamin B6 precursor, pyridoxal, to the biologically active form, PLP.
7 
Thus, in theory, inadequate intake of riboflavin might give rise to 
increased plasma Hcy.7 In addition, riboflavin deficiency may exert 
some of its effects on Hcy by reducing the metabolism of other B 
vitamins, notably those of folate and vitamin B6.
42
Riboflavin intake emerged as a factor that influences Hcy in 
the Framingham Offspring cohort.43 By contrast, Verhoef and 
96
Review: Dietary strategies to treat hyperhomocysteinaemia based on the biochemistry of homocysteine
2014;27(3)S Afr J Clin Nutr
De Groot27 reported that riboflavin has little influence on fasting 
Hcy concentrations. It may be relevant in individuals with the MTHFR 
677 TT genotype, as riboflavin status was reported to be a modulator 
of Hcy in healthy adults, especially in those homozygous for the 
MTHFR C677T mutation.44 Moat et al45 confirmed a folate‑riboflavin 
interaction in determining Hcy unrelated to the MTHFR genotype.
Vitamin B6 status
Reduced vitamin B6 causes an accumulation of Hcy because CBS 
and CSE, which catalyse the trans‑sulphuration of Hcy, are vitamin 
B6 dependent.
46 The metabolism of vitamin B6 is flavin dependent and 
impaired synthesis of PLP in the presence of a riboflavin deficiency 
has been demonstrated in studies on humans and animals.47 
McKinley et al48 reported that low‑dose vitamin B6 supplementation 
effectively lowers Hcy in healthy elderly persons who are both folate 
and riboflavin replete.
Vitamin B6 supplementation has little influence on fasting Hcy 
concentrations, although it may improve Hcy catabolism in elderly 
individuals.27 It significantly reduces the post‑methionine load 
increase in Hcy, and also reduces cystathionine concentrations, 
probably owing to enhanced CSE activity.49
Vitamin B12 status
Folate and cobalamin (as methylcobalamin) are involved as substrate 
and coenzyme, respectively, in the remethylation pathway of Hcy to 
methionine. Plasma Hcy increases considerably when there is an 
intracellular deficiency of folate or cobalamin, and is regarded as a 
sensitive marker of suboptimal vitamin concentrations.25
Vitamin B12 deficiencies are most commonly because of problems 
of malabsorption, e.g. alcoholism47 or inadequate dietary intake, 
especially in individuals who follow a strict vegetarian diet since 
vitamin B12 is found only in animal‑source foods.
50 A reduced vitamin 
B12 status prevents the proper functioning of the methylation cycle by 
directly reducing the activity of MS, one of the enzymes needed for the 
methylation cycle to turn.7 The enzyme, MS, is dependent on 5‑MTHF 
as a methyl donor, but also on vitamin B12 as methylcobalamin.
7 
A low vitamin B12 status may alter Hcy by reducing its remethylation 
cycle towards methionine resynthesis in the same manner that low 
folate status alters Hcy metabolism.26
Certain rare and drastic genetic mutations, such as the one described 
by Mudd et al in 1969,51 can lead to impaired vitamin B12 activation. 
This results in reduced MS activity, with a rise in urinary and plasma 
Hcy, as well as a reduction in the activity of methylmalonyl‑CoA 
mutase (the other vitamin B12‑dependent enzyme), causing an 
accumulation of methylmalonic acid.51
Dietary lipotropics
Methionine, betaine and choline belong to a group of compounds 
called lipotropics.52 Lipotropics are compounds that have an affinity 
for lipids, and thus prevent or correct the excess accumulation of fat 
in the liver by promoting the transport of fatty acids from the liver to 
the tissues, or by accelerating the utilisation of fat in the liver itself.
Methionine
Methionine is an essential amino acid that is naturally found in dietary 
proteins. A typical Western diet contains 1.6‑2.8 g of methionine per 
day,53 which is more than that required for protein biosynthesis. Thus, 
the excess must be catabolised.7 The transamination of methionine 
only occurs at non‑physiologically high concentrations, and instead, 
methionine catabolism takes place mainly in the liver, through its 
sequential conversion to SAM and SAH, and then to Hcy, followed by 
the trans‑sulphuration pathway.7
For this reason, methionine loading tests (MLT) are often used to 
induce “stress” on Hcy metabolism, and could reveal any defect 
in Hcy metabolism (methionine intolerance) and cause a transient 
acute increase in Hcy concentrations. MLT permit the screening of 
40‑55% of persons54 who may have clinically relevant HHcy which 
fasting Hcy determination alone may fail to identify. Ubbink et al55 
reported that the rise in Hcy after methionine loading is lower in 
black Africans than in Caucasians, which points towards a more 
effective Hcy metabolism. This seems to correlate with the lower 
prevalence of CVD seen in these subjects. Caucasians with an 
elevated risk of CVD showed higher Hcy concentrations after oral 
MLT.56 It has been suggested that methionine handling capacity is 
more dependent on (genetically determined) enzyme activities, but 
fasting (basal) Hcy concentrations are more strongly influenced by 
environmental factors.57
Oral MLT is associated with a small, but significant, enhancement 
of thrombin generation,58 and is associated with impaired 
flow‑mediated, endothelium‑dependent vasodilatation.59 Even 
low‑dose methionine and animal protein intake was reported to 
increase Hcy and lead to the rapid onset of endothelial dysfunction,60 
suggesting that even diet‑related increments in Hcy may contribute 
to the development and progression of atherosclerosis.  It is unknown 
whether or not a diet that is rich in animal protein containing large 
amounts of methionine might activate platelets, increase thrombin 
production or induce endothelial dysfunction.
Betaine and choline intake
Betaine or trimethylglycine, and its precursor, choline, are major 
sources of methyl groups (one‑carbon nutrients) in the diet,61 
and thus can act as methyl donors in Hcy remethylation. Betaine 
generates methionine and SAM, then converts Hcy to methionine, 
using the enzyme, BHMT, independent of folate or vitamin B
12.
7 
Betaine can be found in food and it is estimated that a normal diet 
contains 0.5‑2 g/day or can be synthesised endogenously from 
choline, also found in food.62 Choline is derived from the diet, as well 
as from de novo synthesis.63
The consumption of betaine and choline can lower fasting Hcy 
concentrations to the same extent as folic acid, particularly in the 
setting of a high intake of methionine.27 High doses of betaine (6 g/day 
and higher) can be used as Hcy‑lowering therapy in individuals with 
HHcy because of inborn errors in their Hcy metabolism.  Betaine has 
been reported to lower plasma Hcy in vitamin B
6‑resistant patients.
62 
In addition, betaine supplementation seems to lower fasting Hcy dose 
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dependently, up to 20% for a dose of 6 g/day, in healthy volunteers 
with normal Hcy concentrations. Betaine also reduces the increase 
in Hcy after MLT by up to 50%, whereas folic acid has no effect.62 
Betaine could also lower Hcy independent of folate remethylation in 
the presence of ethanol.64 In this regard, Chiuve et al65 reported that 
total choline and betaine intake was inversely associated with Hcy 
in women, and that the strongest dose response was observed in 
women with a low methyl diet (high alcohol and inadequate folate 
intake). Therefore, Chuive et al65 concluded that the remethylation 
of Hcy may be more dependent on the betaine pathway when 
methyl sources in the diet are low. Betaine and choline depletion in 
animals plays a role in the pathogenesis of homocystinuria owing to 
deficiencies of the MTHFR enzyme.66
Thus, betaine and choline can be important food components that 
attenuate Hcy rises after meals. If Hcy plays a causal role in the 
development of CVD, a diet that is rich in betaine or choline might 
benefit cardiovascular health through its Hcy‑lowering effects. 
However, betaine and choline may adversely affect serum lipid 
concentrations, which can increase the risk of CVD. It remains to be 
established whether or not the potential beneficial health effects of 
betaine and choline outweigh the possible adverse effects on serum 
lipids.
Coffee and tea consumption
The consumption of tea and coffee increases Hcy concentrations by 
up to 20%.27 Habitual coffee drinking is positively associated with Hcy 
concentration in most,43,67‑70 but not all,71‑73 observational studies. 
Intervention trials indicated that the increasing effect of coffee 
consumption on Hcy concentrations may be causal.74‑76 The vitamin 
B6 concentration was markedly lower in a randomised crossover 
trial in the period when coffee was consumed, rather than when no 
coffee was drunk, but since vitamin B6 does not seem to influence 
fasting Hcy concentrations greatly, the significance of this finding 
is uncertain.75 The constituent caffeine, which is a methyl xanthine, 
might be the culprit,43,75 because methyl xanthines are known to 
act as vitamin B6 antagonists that may inhibit the conversion of 
Hcy to Cys.75 The polyphenol, chlorogenic acid, which is present in 
coffee in the same amount as caffeine, may partly contribute to the 
increase in Hcy concentration. When polyphenols are metabolised, 
methyl groups from methionine are necessary, which results in a 
higher production of Hcy.77 Both caffeine and chlorogenic acid are 
also present in tea, although in smaller doses, which explains the 
absence of a clear association between Hcy and tea consumption.77 
The consumption of one litre of strong coffee daily may affect diet 
composition and other lifestyle factors. Therefore, it could influence 
Hcy concentrations indirectly,78 but this has not yet been explored. It 
is also possible that the Hcy response to coffee may be modulated 
by the genetic factors mentioned earlier.78 Since the habit of coffee 
drinking is widespread, consequences at population level may not 
be negligible. However, the effect of coffee consumption on Hcy 
concentration is modest and much less than the changes associated 
with a variation in B vitamin status.
Alcohol consumption
Light to moderate alcohol consumption is associated with reduced 
mortality from CVD (the French paradox).79  However, intermittent 
bouts of excessive consumption (binge drinking) and chronic 
high levels of alcohol consumption result in a sequelae of health 
problems, such as increased CVD (for example, cardiomyopathy 
and arrhythmia) morbidity, neurological disorders, certain cancers, 
chronic pancreatitis and liver cirrhosis.80  Lifelong abstainers appear 
to be at a slightly higher risk than light or moderate consumers 
who are able to control their drinking.81 Therefore, total abstinence 
is unnecessary when the consumer can enjoy alcohol sensibly, but 
abstainers are not advised to start drinking in order to gain any 
claimed health benefits.82
In a meta‑analysis, Bagnardi et al83 reported that regular heavy 
drinkers and heavy irregular binge drinkers showed significantly 
different pooled relative risks of 0.75 (95% CI: 0.64‑0.89) and 1.10 
(95% CI: 1.03‑1.17), respectively, as opposed to abstainers, for 
developing CVD. Therefore, the pattern of drinking, as well as the 
amount consumed, plays a pivotal role in CVD development.
An elevated Hcy concentration is one of the myriad negative 
consequences of chronic alcoholism.84 The Hcy concentration 
seems to be twice as high, and plasma B vitamins lower, in chronic 
alcoholics, than in healthy controls. This is probably because of 
a combination of malnourishment, the direct effects of heavy 
alcohol intake on folate status and vitamin B6 (acetaldehyde 
dislodges vitamin B6 from its protective binding protein so that it is 
destroyed, and alcohol interferes with thiamine, folate and vitamin 
B12 absorption), the decreased hepatic uptake and retention, and 
the increased urinary excretion of folate.85 A major difficulty in 
drawing conclusions about the effect of alcohol consumption on 
Hcy lies in distinguishing between the direct effects of alcohol and 
alcohol‑induced malnutrition. An association between alcohol and 
Hcy has not been detected in some studies,86,87 but it has been 
demonstrated in several that moderate consumption inversely 
relates to Hcy concentration, compared with abstaining.88,89 However, 
moderate alcohol consumption in social drinkers is associated with 
increased Hcy,90 and wine consumption, in particular, relates to Hcy 
in a J‑shaped manner, i.e. Hcy is higher when alcohol consumption 
is high, lower when alcohol consumption is low or moderate, and 
tends to be slightly increased in individuals who do not consume 
any alcohol.68 Thus, the literature on the cardioprotective effects 
of moderate alcohol consumption, compared with non‑drinking, in 
relation to Hcy, remains contentious.
It may be important to distinguish between the effects that can 
be attributed directly to alcohol, and those that may result from 
other constituents of alcoholic drinks. Different types of alcoholic 
beverages seem to influence Hcy in different ways. The results from 
studies to determine the effects of different alcoholic beverages are 
inconsistent.90,91 Beer consumption might be responsible for the 
inverse or absence of an association with alcohol consumption and 
Hcy concentration,43,68,88,91 but some studies report that it is positively 
associated with Hcy.90 Researchers have ascribed the beneficial 
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effect of beer drinking on Hcy to its folate, riboflavin and vitamin B6 
content, all of which are important for enzymatic Hcy conversion. 
Wine consumption seems to elevate Hcy concentrations.90,91 It 
was revealed that Hcy in women showed a U‑shaped curve with 
a minimum of 8.49 mmol/l at 10‑20 g alcohol/day, whereas an 
inverse association was observed in men by Burger et al92 in a large 
cross‑sectional study. Spirits, on the other hand, seem to elevate 
Hcy concentrations.90,91 In Africa, indigenous people brew traditional 
alcoholic beverages, such as sorghum, millet beers and Mbamba, 
the last of which is a concoction of water, bread, oats, pineapple 
juice, sugar and yeast. Sorghum beer has been reported to make 
positive contributions to dietary intake, particularly when the beer 
is brewed with a sorghum adjunct. Hence, the results for different 
types of alcoholic beverages are not clear.
The relationship between alcohol consumption and Hcy concentration 
is complex. Alcohol (ethanol) interferes with both the transmethy‑
lation and trans‑sulphuration pathways of Hcy metabolism, either 
directly,93 or through its metabolite, acetaldehyde,94,95 or through the 
indirect effects mediated by interactions with vitamin metabolism. 
Alcohol studies that have been conducted on humans are scarce, 
and when using chronic alcoholics, the results are often complicated 
by liver disease and/or dietary insufficiencies associated with 
alcohol consumption.
Acetaldehyde inhibits MS activity,96 which could lead to HHcy, 
independent of vitamin status. It has been indicated in animal 
studies that alcohol consumption causes a compensatory increase 
in betaine, a Hcy methyltransferase that generates methionine 
from Hcy.84 Although methionine levels seem to vary, methionine 
adenosyltransferase activity decreases in most, but not in all 
studies.84,97 The SAM to SAH ratio, an important determinant of 
methylation activity, has been reduced in most animal studies.98 
The alcohol intermediate, acetaldehyde, accelerates the intracellular 
degradation of PLP, reducing the PLP content of hepatic cells, 
despite an adequate dietary intake of vitamin B6.
99 This inhibits the 
PLP‑dependent enzymes, CBS and CSE, compromising Hcy trans‑
sulphuration. Nitric oxide production, secondary to augmented Hcy, 
inhibits MS activity, possibly by inactivating cobalamin,100 which 
further disrupts MS activity, despite cobalamin supplementation, 
as well as directly inhibiting MS, owing to acetaldehyde.96 It was 
reported in studies conducted on ethanol‑fed rats that MS inhibition 
raises the “trapping” of folate as 5‑MTHF.93,93
Folate intake, as discussed previously, seems to be inversely 
associated with Hcy concentration, but this relation seems to be 
modified by the MTHFR C677T genotype and alcohol intake. Women 
with the thermolabile variant of MTHFR 677 or moderate alcohol 
intake demonstrated a significantly higher Hcy concentration at a 
low intake of folate, but adequate folate intake minimised these 
differences.28 In addition, the elevation of Hcy in women who 
consumed low folate and drank moderate amounts of alcohol was 
greater in the presence of the variant, MTHFR 677 T allele.28
Summary and conclusion
Since numerous clinical conditions are known to be associated with 
a high Hcy count, a reduction in Hcy concentration may be clinically 
relevant to prevent disease. However, it remains to be determined 
whether or not lowering Hcy would prevent clinical disease outcomes, 
such as stroke events. Randomised controlled trials that incorporate 
the dietary strategies reviewed here should clarify whether or not the 
nature of the observed association between Hcy and these diseases 
is indeed causal. Settling this dispute of causality is necessary 
since various modifiable factors have been identified that could be 
manipulated as a strategy to prevent and treat diseases contingent 
on Hcy if they were found to be causative. As summarised in Table I, 
Hcy can be lowered by the adequate intake of folate, and vitamins B2, 
B6 and B12 (either through a diet containing lots of fruit, vegetables 
and some animal‑derived foods, or the fortification of food with B 
vitamins), as well as betaine and choline, and the proscription of 
heavy irregular (binge) alcohol drinking. Dietary changes can modify 
Hcy concentrations in ways that are relevant to public health. 
Therefore, dietitians are able to manipulate Hcy, thereby raising the 
prospect of disease prevention.
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